Do analysts prefer TRIB or APM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, TRIB or APM?

Aptorum Group has lower revenue, but higher earnings than Trinity Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trinity Biotech $43.79M 0.02 -$37.38M -$1.73 N/A Aptorum Group $430K 9.86 -$1.36M N/A N/A

Is TRIB or APM more profitable?

Aptorum Group has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Company Net Margins Return on Equity Return on Assets Trinity Biotech -70.06% N/A -32.13% Aptorum Group N/A N/A N/A

Does the media prefer TRIB or APM?

In the previous week, Trinity Biotech had 4 more articles in the media than Aptorum Group. MarketBeat recorded 6 mentions for Trinity Biotech and 2 mentions for Aptorum Group. Aptorum Group's average media sentiment score of 0.94 beat Trinity Biotech's score of 0.46 indicating that Aptorum Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trinity Biotech 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aptorum Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate AKAN or TRIB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings and valuation, AKAN or TRIB?

Trinity Biotech has higher revenue and earnings than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akanda $258.08K 16.20 -$45.65M N/A N/A Trinity Biotech $43.79M 0.02 -$37.38M -$1.73 N/A

Is AKAN or TRIB more profitable?

Akanda has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Company Net Margins Return on Equity Return on Assets Akanda N/A N/A N/A Trinity Biotech -70.06% N/A -32.13%

Does the media refer more to AKAN or TRIB?

In the previous week, Trinity Biotech had 1 more articles in the media than Akanda. MarketBeat recorded 6 mentions for Trinity Biotech and 5 mentions for Akanda. Akanda's average media sentiment score of 0.72 beat Trinity Biotech's score of 0.46 indicating that Akanda is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akanda 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trinity Biotech 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MBIO or TRIB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend TRIB or BGMS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer TRIB or BGMS?

In the previous week, Trinity Biotech had 2 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 6 mentions for Trinity Biotech and 4 mentions for Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals' average media sentiment score of 0.47 beat Trinity Biotech's score of 0.46 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trinity Biotech 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cyclacel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer LIMN or TRIB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is LIMN or TRIB more profitable?

Liminatus Pharma has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -299.79% Trinity Biotech -70.06% N/A -32.13%

Trinity Biotech (TRIB) Competitors

$8.45 -0.51 (-5.73%)

Closing price 07/24/2026 03:51 PM Eastern

Extended Trading

$8.34 -0.11 (-1.30%)

As of 07/24/2026 07:34 PM Eastern

Compare

TRIB vs. APM, AKAN, MBIO, BGMS, and LIMN

Should you buy Trinity Biotech stock or one of its competitors? MarketBeat compares Trinity Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trinity Biotech include Aptorum Group (APM), Akanda (AKAN), Mustang Bio (MBIO), Cyclacel Pharmaceuticals (BGMS), and Liminatus Pharma (LIMN). These companies are all part of the "pharmaceutical products" industry.

How does Trinity Biotech compare to Aptorum Group?

Trinity Biotech (NASDAQ:TRIB) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 3.8% of Aptorum Group shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by insiders. Comparatively, 64.0% of Aptorum Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aptorum Group has lower revenue, but higher earnings than Trinity Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.79M	0.02	-$37.38M	-$1.73	N/A
Aptorum Group	$430K	9.86	-$1.36M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aptorum Group has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-70.06%	N/A	-32.13%
Aptorum Group	N/A	N/A	N/A

In the previous week, Trinity Biotech had 4 more articles in the media than Aptorum Group. MarketBeat recorded 6 mentions for Trinity Biotech and 2 mentions for Aptorum Group. Aptorum Group's average media sentiment score of 0.94 beat Trinity Biotech's score of 0.46 indicating that Aptorum Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trinity Biotech	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aptorum Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aptorum Group beats Trinity Biotech on 6 of the 10 factors compared between the two stocks.

How does Trinity Biotech compare to Akanda?

Akanda (NASDAQ:AKAN) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

In the previous week, Trinity Biotech had 1 more articles in the media than Akanda. MarketBeat recorded 6 mentions for Trinity Biotech and 5 mentions for Akanda. Akanda's average media sentiment score of 0.72 beat Trinity Biotech's score of 0.46 indicating that Akanda is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akanda	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trinity Biotech	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Akanda has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%.

Company	Net Margins	Return on Equity	Return on Assets
Akanda	N/A	N/A	N/A
Trinity Biotech	-70.06%	N/A	-32.13%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

1.0% of Akanda shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 20.4% of Akanda shares are held by company insiders. Comparatively, 8.2% of Trinity Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Trinity Biotech has higher revenue and earnings than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akanda	$258.08K	16.20	-$45.65M	N/A	N/A
Trinity Biotech	$43.79M	0.02	-$37.38M	-$1.73	N/A

Summary

Akanda and Trinity Biotech tied by winning 5 of the 10 factors compared between the two stocks.

How does Trinity Biotech compare to Mustang Bio?

Mustang Bio (NASDAQ:MBIO) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

10.0% of Mustang Bio shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 4.0% of Mustang Bio shares are owned by company insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Trinity Biotech had 4 more articles in the media than Mustang Bio. MarketBeat recorded 6 mentions for Trinity Biotech and 2 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 1.43 beat Trinity Biotech's score of 0.46 indicating that Mustang Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Mustang Bio	Positive
Trinity Biotech	Neutral

Mustang Bio has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat Mustang Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-35.38%	-16.36%
Trinity Biotech	-70.06%	N/A	-32.13%

Mustang Bio has higher earnings, but lower revenue than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A
Trinity Biotech	$43.79M	0.02	-$37.38M	-$1.73	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Mustang Bio and Trinity Biotech tied by winning 6 of the 12 factors compared between the two stocks.

How does Trinity Biotech compare to Cyclacel Pharmaceuticals?

Trinity Biotech (NASDAQ:TRIB) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Trinity Biotech had 2 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 6 mentions for Trinity Biotech and 4 mentions for Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals' average media sentiment score of 0.47 beat Trinity Biotech's score of 0.46 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trinity Biotech	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cyclacel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cyclacel Pharmaceuticals has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-70.06%	N/A	-32.13%
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

Cyclacel Pharmaceuticals has lower revenue, but higher earnings than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.79M	0.02	-$37.38M	-$1.73	N/A
Cyclacel Pharmaceuticals	$1.53M	3.31	-$3M	-$4.54	N/A

Summary

Trinity Biotech beats Cyclacel Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Trinity Biotech compare to Liminatus Pharma?

Liminatus Pharma (NASDAQ:LIMN) and Trinity Biotech (NASDAQ:TRIB) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Liminatus Pharma has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
Trinity Biotech	-70.06%	N/A	-32.13%

79.0% of Trinity Biotech shares are owned by institutional investors. 19.4% of Liminatus Pharma shares are owned by insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Liminatus Pharma has higher earnings, but lower revenue than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
Trinity Biotech	$43.79M	0.02	-$37.38M	-$1.73	N/A

In the previous week, Trinity Biotech had 4 more articles in the media than Liminatus Pharma. MarketBeat recorded 6 mentions for Trinity Biotech and 2 mentions for Liminatus Pharma. Trinity Biotech's average media sentiment score of 0.46 beat Liminatus Pharma's score of 0.44 indicating that Trinity Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Liminatus Pharma	Neutral
Trinity Biotech	Neutral

Summary

Trinity Biotech beats Liminatus Pharma on 6 of the 11 factors compared between the two stocks.

Get Trinity Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRIB vs. The Competition

Export

Metric	Trinity Biotech	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.01M	$8.49B	$6.87B	$12.26B
Dividend Yield	N/A	2.52%	2.67%	9.79%
P/E Ratio	-4.88	18.51	27.14	23.64
Price / Sales	0.02	5.78	517.06	88.99
Price / Cash	N/A	18.17	50.54	59.64
Price / Book	-0.42	3.19	10.28	6.07
Net Income	-$37.38M	$230.22M	$3.60B	$331.99M
7 Day Performance	2,417.17%	21.66%	-1.27%	-0.63%
1 Month Performance	2,319.80%	20.22%	-0.37%	-2.00%
1 Year Performance	151.90%	-4.55%	18.30%	13.62%

Trinity Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRIB Trinity Biotech	0.9852 of 5 stars	$8.45 -5.7%	N/A	+141.6%	$1.01M	$43.79M	N/A	480	Short Interest Decrease Gap Up High Trading Volume
APM Aptorum Group	0.5027 of 5 stars	$0.81 +0.5%	N/A	-96.2%	$5.09M	$430K	N/A	30
AKAN Akanda	1.2792 of 5 stars	$9.39 -2.0%	N/A	-91.3%	$5.07M	$260K	N/A	110	News Coverage Analyst Upgrade Short Interest Decrease Gap Down
MBIO Mustang Bio	1.3982 of 5 stars	$0.66 flat	N/A	-72.3%	$5.03M	N/A	N/A	100	Positive News Short Interest Decrease
BGMS Cyclacel Pharmaceuticals	0.9402 of 5 stars	$0.91 +0.3%	N/A	N/A	$5.02M	$750K	N/A	14	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRIB) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trinity Biotech (TRIB) Competitors

TRIB vs. APM, AKAN, MBIO, BGMS, and LIMN

How does Trinity Biotech compare to Aptorum Group?

Summary

How does Trinity Biotech compare to Akanda?

Summary

How does Trinity Biotech compare to Mustang Bio?

Summary

How does Trinity Biotech compare to Cyclacel Pharmaceuticals?

Summary

How does Trinity Biotech compare to Liminatus Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRIB vs. The Competition

Trinity Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trinity Biotech (TRIB) Competitors

TRIB vs. APM, AKAN, MBIO, BGMS, and LIMN

How does Trinity Biotech compare to Aptorum Group?

Do institutionals & insiders believe in TRIB or APM?

Which has higher valuation and earnings, TRIB or APM?

Do analysts prefer TRIB or APM?

Is TRIB or APM more profitable?

Does the media prefer TRIB or APM?

Summary

How does Trinity Biotech compare to Akanda?

Does the media refer more to AKAN or TRIB?

Is AKAN or TRIB more profitable?

Do analysts rate AKAN or TRIB?

Do institutionals & insiders believe in AKAN or TRIB?

Which has stronger earnings and valuation, AKAN or TRIB?

Summary

How does Trinity Biotech compare to Mustang Bio?

Do institutionals and insiders have more ownership in MBIO or TRIB?

Does the media refer more to MBIO or TRIB?

Is MBIO or TRIB more profitable?

Which has preferable earnings and valuation, MBIO or TRIB?

Do analysts recommend MBIO or TRIB?

Summary

How does Trinity Biotech compare to Cyclacel Pharmaceuticals?

Do insiders and institutionals hold more shares of TRIB or BGMS?

Do analysts recommend TRIB or BGMS?

Does the media prefer TRIB or BGMS?

Is TRIB or BGMS more profitable?

Which has stronger valuation & earnings, TRIB or BGMS?

Summary

How does Trinity Biotech compare to Liminatus Pharma?

Is LIMN or TRIB more profitable?

Do institutionals & insiders believe in LIMN or TRIB?

Do analysts prefer LIMN or TRIB?

Which has preferable valuation and earnings, LIMN or TRIB?

Does the media prefer LIMN or TRIB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRIB vs. The Competition

Trinity Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools